Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Zhendong Pharmaceutical Secures China Promotion Rights to Ferring’s Sodium Picosulfate

Fineline Cube Feb 10, 2026
Company Deals

GenAssist Therapeutic Partners with Indian DART Foundation on Duchenne Muscular Dystrophy Base Editing

Fineline Cube Feb 10, 2026
Company Deals

Foresee Pharmaceuticals Licenses MMP-12 Inhibitor Portfolio to Primevera for $584.5 Million

Fineline Cube Feb 10, 2026
Company Deals

Formosa Pharmaceuticals Licenses APP13007 Eye Drops to Samil Pharma for South Korea Market

Fineline Cube Feb 10, 2026
Company Deals

Nanjing Hanxin Licenses AC02 ACTH Analogue to Amphastar for $151 Million US/Canada Deal

Fineline Cube Feb 10, 2026
Policy / Regulatory

Guangdong Unveils Expanded 2025 Greater Bay Area Access List for 115 Hong Kong and Macao Drugs and Devices

Fineline Cube Feb 9, 2026
Company Deals Drug

Huadong Medicine and Shian Biotech Advance siRNA Obesity Therapy to Preclinical Stage

Fineline Cube Feb 10, 2026
Company Drug

Delonix Bioworks’ DX-104 Becomes First China-Approved Engineered OMV Vaccine, Targets $1.3 Billion MenB Market

Fineline Cube Feb 9, 2026
Company

Jiangsu Wuzhong Pharma Faces Forced Delisting After CSRC Investigation

Fineline Cube Apr 17, 2025

China-based Jiangsu Wuzhong Pharmaceutical Group Corp. (SHA: 600200) has disclosed a potential forced delisting from...

Company Drug

Sichuan Biokin’s BL-M09D1 ADC Receives NMPA Clinical Trial Clearance for Solid Tumors

Fineline Cube Apr 17, 2025

Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506) has announced that its antibody-drug conjugate (ADC) BL-M09D1...

Company Deals

Da Ren Tang Sells Stake in Tianjin Shike to Haleon for RMB 1.623 Billion

Fineline Cube Apr 17, 2025

Tianjin Pharmaceutical Da Ren Tang Group Co., Ltd. (SHA: 600329), a traditional Chinese medicine (TCM)...

Company Deals Drug

Akeso Biopharma Partners with Virogin to Test Ivonescimab and VG201 in Colorectal Cancer Trial

Fineline Cube Apr 17, 2025

China-based Akeso Biopharma (HKG: 9926) has entered into a clinical collaboration with Virogin Biotech Co.,...

Company Deals

Berry Genomics Collaborates with Beijing Children’s Hospital on Newborn Birth Defects Screening Project

Fineline Cube Apr 17, 2025

China-based genomics testing company Berry Genomics (SHE: 000710) has entered into a project achievement translation...

Policy / Regulatory

Trump Orders HHS to Reduce Drug Prices, Revamp Medicare Negotiation Program

Fineline Cube Apr 17, 2025

President Donald Trump issued a new Executive Order aimed at reducing drug prices for American...

Company Drug

Galderma Launches Sculptra in China as First Regenerative Biostimulator

Fineline Cube Apr 16, 2025

Switzerland-based skin care specialist Galderma officially launched Sculptra in China this week, marking the first...

Company Drug

Easton Pharma’s EP-9001A Shows Promising Results in Phase Ib for Bone Metastasis Cancer Pain

Fineline Cube Apr 16, 2025

Chengdu-based Easton Pharmaceutical Co., Ltd (SHA: 688513) has announced preliminary statistical analysis results from the...

Company Medical Device

Edwards Lifesciences Gains EU CE Mark for SAPIEN M3 Mitral Valve System

Fineline Cube Apr 16, 2025

US medical device giant Edwards Lifesciences Corporation (NYSE: EW) has announced that it has received...

Company Drug

InnoCare Pharma’s Zurletrectinib NDA Accepted by China’s CDE for TRK Fusion Cancers

Fineline Cube Apr 16, 2025

Beijing-based biopharmaceutical company InnoCare Pharma (HKG: 9969, SHA: 688428) has announced that China’s Center for...

Policy / Regulatory

NHC Releases Standardized Family Doctor Service Packages for Key Demographic Groups

Fineline Cube Apr 16, 2025

The National Health Commission (NHC) has issued the “List of Basic Service Packages for Family...

Company Deals Medical Device

Kosell Medtech Partners with Wenzhou Medical University on K-Sheath System

Fineline Cube Apr 16, 2025

China-based Kossel Medtech (Suzhou) Co., Ltd., a vascular interventional medical device platform company, has entered...

Company Drug

Sichuan Biokin Secures Four Phase II Approvals for BL-B01D1 in Combination Therapies

Fineline Cube Apr 16, 2025

China-based Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506) has announced that it has secured four...

Company Drug

Hansoh Pharmaceutical Gains Clinical Approval for KRAS G12D Targeted Drug HS-10529

Fineline Cube Apr 16, 2025

China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) has announced that it has received clinical...

Company Drug

AccurEdit Therapeutics Reports Positive 24-Week Data for ART002 in HeFH Patients

Fineline Cube Apr 16, 2025

Suzhou-based gene editing specialist AccurEdit Therapeutics has announced the completion of a 24-week follow-up for...

Company Deals

Cyprumed Signs Non-Exclusive License Agreement with MSD for Oral Peptide Delivery Tech

Fineline Cube Apr 16, 2025

Germany-based Cyprumed GmbH has entered into a non-exclusive license and option agreement with Merck, Sharp...

Company Drug Policy / Regulatory

US Commerce Department Launches Section 232 Probe on Pharma Imports and National Security

Fineline Cube Apr 16, 2025

The US Department of Commerce (DoC) has initiated a Section 232 investigation to evaluate the...

Company

Johnson & Johnson Reports Q1 2025 Revenue Growth, Led by Innovative Medicines and MedTech

Fineline Cube Apr 16, 2025

US pharmaceutical giant Johnson & Johnson (J&J, NYSE: JNJ) reported Q1 2025 revenues of USD...

Company Drug

BMS Faces Phase III Setback for Camzyos in Non-Obstructive HCM Study

Fineline Cube Apr 15, 2025

US pharmaceutical giant Bristol-Myers Squibb (BMS; NYSE: BMY) has reported a setback in the Phase...

Company Drug

Beijing Wantai Launches Phase III Trial for 9-Valent HPV Vaccine in Chinese Males

Fineline Cube Apr 15, 2025

China-based Beijing Wantai Biological Pharmacy Enterprise Co., Ltd (SHA: 603392) has initiated a Phase III...

Posts pagination

1 … 133 134 135 … 622

Recent updates

  • Xianju Pharmaceutical and Adamerck Grant Aspen China Rights to Aomeikesong Neuromuscular Reversal Agent
  • Zhendong Pharmaceutical Secures China Promotion Rights to Ferring’s Sodium Picosulfate
  • GenAssist Therapeutic Partners with Indian DART Foundation on Duchenne Muscular Dystrophy Base Editing
  • Foresee Pharmaceuticals Licenses MMP-12 Inhibitor Portfolio to Primevera for $584.5 Million
  • Formosa Pharmaceuticals Licenses APP13007 Eye Drops to Samil Pharma for South Korea Market
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Digital

Xianju Pharmaceutical and Adamerck Grant Aspen China Rights to Aomeikesong Neuromuscular Reversal Agent

Company Deals

Zhendong Pharmaceutical Secures China Promotion Rights to Ferring’s Sodium Picosulfate

Company Deals

GenAssist Therapeutic Partners with Indian DART Foundation on Duchenne Muscular Dystrophy Base Editing

Company Deals

Foresee Pharmaceuticals Licenses MMP-12 Inhibitor Portfolio to Primevera for $584.5 Million

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.